Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.43 EUR | -1.38% | -1.38% | -8.33% |
Jun. 12 | Ikonisys, Ulisse Biomed to Collaborate on New Cancer Diagnostic Technologies | MT |
Jun. 03 | Ikonisys S.A. announced that it has received ?1.150001 million in funding | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Capitalization 1 | 27.5 | 13.75 | 15.3 | 15.3 | - |
Enterprise Value (EV) 1 | 27.5 | 13.75 | 16.9 | 15.3 | 11.5 |
P/E ratio | -48.3 x | -5.62 x | -9.06 x | 72.5 x | 12.1 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | 59.2 x | 14.7 x | 15.3 x | 3.12 x | 1.29 x |
EV / Revenue | 59.2 x | 14.7 x | 16.9 x | 3.12 x | 0.97 x |
EV / EBITDA | -82.9 x | -5.7 x | -24.1 x | 19.1 x | 4.79 x |
EV / FCF | -20.3 x | -12 x | -8.89 x | 9.56 x | 3.03 x |
FCF Yield | -4.94% | -8.36% | -11.2% | 10.5% | 33% |
Price to Book | 1.37 x | - | 1.02 x | 1.01 x | 0.92 x |
Nbr of stocks (in thousands) | 9,482 | 9,482 | 10,551 | 10,551 | - |
Reference price 2 | 2.900 | 1.450 | 1.450 | 1.450 | 1.450 |
Announcement Date | 4/29/22 | 4/29/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net sales 1 | 0.4642 | 0.9352 | 1 | 4.9 | 11.9 |
EBITDA 1 | -0.3317 | -2.411 | -0.7 | 0.8 | 2.4 |
EBIT 1 | -0.4123 | -2.435 | -1.8 | 0.2 | 1.5 |
Operating Margin | -88.81% | -260.34% | -180% | 4.08% | 12.61% |
Earnings before Tax (EBT) 1 | -0.4174 | -2.448 | -1.9 | 0.2 | 1.5 |
Net income 1 | -0.5713 | -2.448 | -1.9 | 0.2 | 1.5 |
Net margin | -123.05% | -261.79% | -190% | 4.08% | 12.61% |
EPS 2 | -0.0600 | -0.2582 | -0.1600 | 0.0200 | 0.1200 |
Free Cash Flow 1 | -1.357 | -1.149 | -1.9 | 1.6 | 3.8 |
FCF margin | -292.39% | -122.87% | -190% | 32.65% | 31.93% |
FCF Conversion (EBITDA) | - | - | - | 200% | 158.33% |
FCF Conversion (Net income) | - | - | - | 800% | 253.33% |
Dividend per Share | - | - | - | - | - |
Announcement Date | 4/29/22 | 4/29/23 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net Debt 1 | - | - | 1.6 | - | - |
Net Cash position 1 | - | - | - | - | 3.8 |
Leverage (Debt/EBITDA) | - | - | -2.286 x | - | - |
Free Cash Flow 1 | -1.36 | -1.15 | -1.9 | 1.6 | 3.8 |
ROE (net income / shareholders' equity) | -3.26% | - | -11.4% | 1.2% | 8.3% |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share 2 | 2.110 | - | 1.420 | 1.440 | 1.570 |
Cash Flow per Share 2 | -0.0800 | - | -0.1000 | 0.1500 | 0.3600 |
Capex 1 | 0.58 | 0.86 | 1.2 | 0.6 | 0.9 |
Capex / Sales | 124.07% | 92.29% | 120% | 12.24% | 7.56% |
Announcement Date | 4/29/22 | 4/29/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.69% | 16.6M | |
-2.58% | 8.27B | |
+7.84% | 5.81B | |
+29.76% | 5.58B | |
-15.77% | 3.85B | |
+12.42% | 2.71B | |
-61.85% | 2.56B | |
-4.98% | 2.42B | |
+23.09% | 2.13B | |
-9.25% | 1.77B |
- Stock Market
- Equities
- ALIKO Stock
- Financials Ikonisys S.A.